⚕ GalenOps CRO console
← 708 (USA)

708-1428

completed
Study: Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. Phase II · Site: 708 (USA) (Dr. Kim) · consented 2013-11-09
Adverse events
7
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Moderate APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-10 (study day 32.0); relationship: PROBABLE

severe assessed 2026-08-18

Severe APPLICATION SITE ERYTHEMA — outcome: RECOVERED/RESOLVED; onset 2013-12-10 (study day 32.0); relationship: PROBABLE

moderate assessed 2026-08-18

Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-10 (study day 32.0); relationship: PROBABLE

severe assessed 2026-08-18

Severe APPLICATION SITE PRURITUS — outcome: RECOVERED/RESOLVED; onset 2013-12-10 (study day 32.0); relationship: PROBABLE

moderate assessed 2026-08-18

Moderate APPLICATION SITE WARMTH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-10 (study day 32.0); relationship: PROBABLE

severe assessed 2026-08-18

Severe APPLICATION SITE WARMTH — outcome: RECOVERED/RESOLVED; onset 2013-12-10 (study day 32.0); relationship: PROBABLE

mild assessed 2026-08-18

Mild EPISTAXIS — outcome: RECOVERED/RESOLVED; onset 2013-11-22 (study day 14.0); relationship: REMOTE

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.